Literature DB >> 1797598

Dose-dependent effects of fentanyl on indomethacin-induced gastric damage.

R J Playford1, D A Vesey, S Haldane, M R Alison, J Calam.   

Abstract

Whilst developing a rat model for studies of gastric protection, we noticed that the anaesthetic agent 'Hypnorm', containing the opiate fentanyl 0.315 mg/ml and the butyrophenone fluanisone 10 mg/ml, was itself protective against indomethacin-induced damage: unrestrained animals given indomethacin (20 mg/kg) subcutaneously had an ulcer score of 9 +/- 1 mm2, compared with 1 +/- 1 mm2 in animals pre-treated with Hypnorm (0.8 ml/kg) and then given indomethacin (p less than 0.01). Further investigation showed this effect to be due to fentanyl-inhibiting gastric acid secretion: doses of fentanyl (90 and 180 micrograms/kg) which decreased indomethacin-induced damage also caused a rise in intragastric pH from 2.7 +/- 0.6 in controls to 5.1 +/- 0.8 and 5.0 +/- 0.8, respectively. However, the response of fentanyl varied depending on the dose given: fentanyl, 3.6 micrograms/kg did not affect indomethacin-induced damage, 8 +/- 2 vs. 9 +/- 1 mm2; fentanyl, 18 micrograms/kg potentiated damage, 15 +/- 4 mm2 (p less than 0.05), whereas fentanyl, 90 micrograms/kg and 180 micrograms/kg decreased damage, 2 +/- 1 mm2 and 0.1 +/- 0.1 mm2, respectively (p less than 0.01). Neither the butyrophenone haloperidol (8.3 mg/kg) nor the alpha-adrenergic receptor antagonist phenoxybenzamine (3 mg/kg) protected against indomethacin-induced damage. We conclude that fentanyl affects intragastric pH and can both potentiate and protect against indomethacin-induced damage. Furthermore, the potentiation of gastric damage by fentanyl occurred at doses similar to those used for human anesthesia, so clinical studies are suggested.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797598     DOI: 10.1159/000200722

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  7 in total

1.  Role of capsaicin sensitive nerves in epidermal growth factor effects on gastric mucosal injury and blood flow.

Authors:  J Y Kang; C H Teng; F C Chen; A Wee
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

2.  Bovine colostrum is a health food supplement which prevents NSAID induced gut damage.

Authors:  R J Playford; D N Floyd; C E Macdonald; D P Calnan; R O Adenekan; W Johnson; R A Goodlad; T Marchbank
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

3.  Reparative properties of a commercial fish protein hydrolysate preparation.

Authors:  A J Fitzgerald; P S Rai; T Marchbank; G W Taylor; S Ghosh; B W Ritz; R J Playford
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

4.  Human transforming growth factor alpha (TGF-alpha) is digested to a smaller (1-43), less biologically active, form in acidic gastric juice.

Authors:  T Marchbank; R Boulton; H Hansen; R J Playford
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

5.  Potency and stability of C terminal truncated human epidermal growth factor.

Authors:  D P Calnan; A Fagbemi; J Berlanga-Acosta; T Marchbank; T Sizer; K Lakhoo; A D Edwards; R J Playford
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

6.  Opioid Use in Murine Model Results in Severe Gastric Pathology that May Be Attenuated by Proton Pump Inhibition.

Authors:  Nillu Ghosh; Kousik Kesh; Sundaram Ramakrishnan; Sabita Roy
Journal:  Am J Pathol       Date:  2022-05-20       Impact factor: 5.770

7.  Marked variability in bioactivity between commercially available bovine colostrum for human use; implications for clinical trials.

Authors:  Raymond J Playford; Meg Cattell; Tania Marchbank
Journal:  PLoS One       Date:  2020-06-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.